The human T cell response to the myelin basic protein (MBP) has been studied with respect to T cell receptor (TCR) peptide of which is currently being used in a clinical trial for treatment of MS patients, was expressed by only one of our TCL. However, within this complex pattern of MBP-specific T cell responses, a minority of MS patients were found to exhibit a more restricted response with respect to their TCL epitope specificity. In these patients 75-87% of the TCL responded to a single, patient-specific cluster of immunodominant T cell epitopes located within a small (20-amino acid) domain of MBP.
Introduction
There are several reasons to consider myelin basic protein (MBP)' as a candidate autoantigen involved in the immunopathogenesis of multiple sclerosis (MS) (1, 2) . MBP is a strong encephalitogen in many animal species, and MBP-specific T cells have been found in experimental (3) and human postviral encephalitis (4) . The frequency of MBP-reactive T cells is increased in the cerebrospinal fluid of MS patients (5) , and MBP-specific T cells in the blood of MS patients display increased rates of somatic mutation, presumably reflecting sustained cell proliferation (6) . Further, T cell receptor (TCR) V/3-Df%-Jf motifs similar to those found in MBP-specific T cell lines (TCL) were amplified from an MS brain (7) .
Although these arguments are indirect (6, 8, 9) , they justify the intensive research devoted to the human T cell response against MBP over the past years. A key issue raised by these studies is the heterogeneity of the human T cell response to MBP. Unlike the response to MBP in inbred animal strains, there seems to be a broader diversity ofTCR usage and epitope specificity in MS patients (10) (11) (12) (13) (14) (15) (16) (17) .
Here we present the analysis of a large panel of MBP-specific long-term TCL generated using the "split well" primary cloning technique. We found in most cases an amazing variety of MBP epitopes, restricting MHC class II molecules, and TCR elements involved in the human T cell response against MBP. However, in some MS patients the MBP-specific T cell response was directed against specific domains of the molecule that contained a cluster of immunodominant epitopes. In one patient, reactivity against the individual immunodominant epitope cluster has been observed for 2 yr, and identical TCR VA sequences have been found in TCL generated at different time points.
Methods
Peripheral blood cells. PBMC were obtained by centrifugation of standard discontinuous density gradients (Nycomed, Oslo, Norway) from 13 patients with laboratory-supported definite MS (18) , and from 10 healthy donors. Sex, age, HLA-types, and clinical details are listed in Table I .
Purification of human MBP. Adult human brain tissue was obtained within 24 h after death and frozen at -80'C. MBP was purified according to established protocols (19) . Briefly, homogenized brain matter was subjected sequentially to delipidation, acid extraction, neutralization, ammonium sulfate precipitation, and acetone precipitation. Purity of the MBP preparations was assessed by gel electrophoresis.
Synthesis ofMBPpeptides. Peptides were synthesized usingan automatic peptide synthesizer (431A; Applied Biosystems, Inc., Foster City, CA) according to the fluorenyl methoxycarbonyl method and purified by FPLC Isolation of MBP-specific TCL. MBP-specific TCL were established using the "split-well method," which allows the rapid isolation of clonal populations ofantigen-specific CD4+ TCL (20) . Briefly, 2 x I05 PBMC were seeded in 200 Nl medium (RPMI supplemented with 2 mM L-glutamine, 100 U/ml of penicillin, 100 ug/ml of streptomycin [all from Gibco, Berlin, Germany]), and 5% pooled human AB serum in 96-well round-bottomed microtiter plates (Nunc, Roskilde, Denmark) in the presence of 30 qg/ml MBP. Every 3-4 d the cells were fed with 100 l medium containing 3 U recombinant IL-2 (rIL-2; Hoffmann-La Roche Inc., Basel, Switzerland). After 2-3 wk the contents of each well were split between two wells, MBP was added to one of the wells, and 2 x 105 irradiated autologous PBMC were added to both wells. The cultures were scanned microscopically for antigen-specific proliferation. Specifically responding populations were selected for further expansion.
Characterization ofTCL byflow cytometry. Supernatants ofhybridoma cultures (American Type Culture Collection, Rockville, MD) were used as the source for mAbs recognizing CD3 (OKT3), CD4 (OKT4), CD8 (OKT8), and HLA-DR (L243). The mAbs against TCR V region determinants came from T Cell Sciences (Cambridge, MA). These antibodies bind to V35. X 106 T cells as described (27) . Oligo(dT)-primed double-stranded cDNA was synthesized from 2-3 pg of total RNA using Moloney murine leukemia virus-derived reverse transcriptase (GIBCO BRL, Gaithersburg, MD) essentially as described by the supplier. Bluntended cDNA was then circularized during a 5-h incubation at room temperature with T4 DNA ligase (GIBCO BRL) in a volume of 20 pl. The ligated material (1,l) was used as a template for an inverse PCR basically as described (28) . cycles (denaturation at 94°C for 1 min, annealing at 55°C for 1 min, and extension at 72°C for 1 min). PCR products were purified by phenol extraction, precipitated with ethanol, and excessively digested with the restriction endonucleases mentioned above. Fragments of expected sizes for the cDNAs were recovered from a preparative low melting point agarose gel and ligated into Ml 3mpl 8 previously cut with EcoRI and BamHI. Single plaques were picked and grown up, and recombinant phage DNA was purified for DNA sequence determination. For each T cell clone three to five independent isolates were sequenced by using the Taq cycle sequencing kit and a 373A DNA sequencer (Applied Biosystems, Inc.).
Results

MBP-specific TCL
In this study, we analyzed the antigen recognition of 136 MBPspecific TCL from 13 MS patients and 79 TCL from 10 healthy donors. All TCL were generated with the "split well" cloning technique using native human MBP as the selecting antigen (20) . The yield of TCL using the split well technique was similar between MS patients and healthy donors. All TCL expressed the phenotype CD3+CD4+HLA-DR+. Approximately 5% of the TCL from MS patients and from healthy donors contained a subpopulation ofCD4+CD8 + double-positive cells.
Among the TCL cultured for 6-8 wk, -85% were essentially monoclonal, as defined by the pattern ofepitope recognition. About 85% of the individual cell lines reacted either with one single or with overlapping peptides (Figs. 1 and 2 ). sis of the TCR usage both at the mRNA level (see Table VI (Table II) . Furthermore, 11% of the MBPspecific TCL did not recognize any of the synthetic peptides. Although all 17 peptides were recognized by at least one MBP-specific TCL, certain peptides were recognized more frequently than others. The most immunogenic region of MBP was located in two peptides spanning position 80-105. This region was recognized by 42 of 136 (31% ) MBP-specific TCL from MS patients.
The epitopes of MBP-specific T cells from healthy donors were also broadly distributed (Fig. 3 B (Table III) . (Table III) , the three DRB1 *0301-restricted TCL recognized peptide 29-48 (Table III) The complexity of human T cell epitopes of MBP, which was so far described on the population level, was also noted within individual donors, MS patients, and healthy volunteers alike. For example, the MBP-specific TCL isolated from patient BM recognized 11 peptides, those from patients EM and PS responded to 9 peptides. The MBP-specific TCL isolated from individual healthy donors also recognized numerous peptides. For example, the TCL from donors GW and FP recognized 10 peptides (Table IV) .
DOMINANCE OF NESTED EPITOPES
In a minority of MS patients (30% of our patients), the anti-MBP response was concentrated within a very small segment of the MBP molecule (Table V) . (Tables IV and V) . Ofnote, the first TCL panel was established during an acute clinical exacerbation, which led to the clinical diagnosis. Since then, the patient has remained in clinical remission, although serial magnetic resonance imaging documented active lesion development over the past 7 mo. A longitudinal study of another MS patient and two normal donors showed that no immunodominant cluster appeared over time (Tables IV and V) .
CLONAL HETEROGENEITY IN DOMINANT ANTI-MBP T CELL RESPONSES
T cell epitopes. The peptide response profiles recognized by TCL indicate that the immunodominant regions identified in our study are composites of several distinct epitopes. This is illustrated in Fig. 1 . In patient K.S., for example, the dominant (Fig. 2) . Table V) . For each patient, all TCL analyzed here were specific for the same peptide. In patient B.M., some but not all TCL specific for peptide 7-26 crossreacted with peptide 1-20, indicating that the TCL recognized different epitopes in the immunodominant region. In patient H.K., TCL were generated at different times (HK 1: TCL generated in June 1990; HK2: TCL generated in June 1991) . Shown are the VB and Ji3 segments (nomenclature according to reference 53) expressed by the TCL and the amino acid sequences of the N-D-N region (one letter code). Several TCR VB transcripts were amplified from some ofthe TCL, indicating that these TCL were oligoclonal rather than monoclonal. ** § Note that in patient H.K., some TCR sequences were identical. Sequence identity was established on the nucleotide level (not shown). 1 1 Nomenclature according to (54) . ' (Table III) . In patient S.S., among the six TCL specific for the immunodominant region 80-105, three TCL were restricted by DRB 1 * 1501, and one line was restricted by DRB5*0I01 (Table III and Fig. 4 ).
Discussion
In this study we have used a technique that allows the isolation of multiple (oligo-)clonal T cell lines directly from the PBMC (20 Our study confirms and extends previous work from our own group (20, 29) , and from other laboratories (30) (31) (32) (33) , that revealed that the spectrum of MBP epitopes recognized by T lymphocytes is much more diverse in humans than in inbred rodents (34) . Our present data document that T cell epitopes can be located in virtually all regions of the human MBP se- consistent with the data presented in a previous study (31) , in which reactivity to a similar peptide (amino acids [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] (36, 37) . Our analysis of HLA restriction demonstrates that the number of HLA class II products presenting MBP epitopes was large. Further, we found three new restriction elements for MBP-specific T cells, including the supertypic determinant DRw52 (DRB3 *0102). Yet, epitope diversity was by no means merely due to the diversity of HLA class II products used for antigen presentation. In fact, one DR heterodimer (DRA/DRB5 *0101) presented at least six distinct MBP epitopes, more than described previously (29, 37) . Finally, we noted marked peptide "promiscuity" with individual peptides being presented by multiple HLA class II products (38) . Peptide 86-105, for example, was presented by DRB5*0101, DRB1 * 1501, DRB1*0401, and DRB3 *0102 in our analysis, and DRB1 *0408 and DRw I3Dw19 in the work by Martin et al. (13) . This astounding promiscuity of many MBP peptides for classII products has been recently documented by direct binding studies (39) .
The TCR V gene repertoire used by MBP-specific human TCL is a controversial issue. Some investigators have emphasized that the usage of TCR V genes is skewed, but there was no consensus about the actual V13 gene dominating the human response (10, 16, 17) . Others have pointed to a more diverse TCR usage (14, 15, 35) . In our panel of MBP-specific TCL we observed a high degree of heterogeneity of TCRVW usage. Each V/3 element that could be identified with the available panel of mAbs was used by MBP-specific T cells from MS patients. No dominance ofany particular Vf3 element shared by any discernible group of patients was evident. Note, however, that the panel of anti-TCR V/3 mAbs that is presently available allows the identification of < 50% of the Vf3 families expressed by human T cells. Thus, a restricted or skewed TCR usage could have escaped this type of analysis.
In our group of patients only 1 of 150 MBP-specific TCL, which were analyzed with anti-TCRV,3 mAbs, expressed
Vf35.2. This is of particular relevance in view of attempts to use peptides from TCR variable chains (e.g., V35.2) for the treatment of MS patients (40) . In a minority of MS patients, at least 75% of TCL responded either to one peptide, or to peptides tightly nested within very narrow segments of the MBP molecule. The dominant epitopes differed between individual donors and were preferentially located in MBP sequences 80-105, 108-131, and 131-153. Also, in normal donors, different MBP-specific TCL may recognize the same peptide. However, the most frequently recognized peptides varied between TCL generated at different times from the same donor (see H.W. and R.V. in Table 5 ).
In one MS patient (H.K.) studied longitudinally, T cell reactivity against one dominant MBP sequence has been observed for > 2 yr. In an initial screening we found that five of six TCL isolated from PBMC recognized MBP sequence 80-105. When reexamined after an interval of1 yr, seven of eight TCL responded against the same peptide, and this dominance could be traced further after another 9 and 12 mo. Similar evidence of persistence of immunodominant epitopes in individual patients has recently been seen in another study (41) .
Interestingly, in this patient we found identical TCR ,B chain sequences in TCL generated at different times (June 1990 and June 1991; see Table VI ). Further, three of the seven sequences from TCL raised in June 1991 were identical. The fact that we found these sequences only in TCL from patient H.K. but not in TCL from B.M. and S.S., which were analyzed Nested Epitopes ofMyelin Basic Protein in Multiple Sclerosis in the same PCR experiments, argues against the possibility that the sequence identities represent PCR artifacts. We favor the interpretation that these sequences derive from (80-105)-specific TCL that were present in the blood of H.K. for an extended period of time and were probably clonally expanded. This would be consistent with previous evidence for clonal expansion of MBP-specific TCL in the blood of MS patients (6) .
Although the first set of TCL from patient H.K. was isolated during a clinical attack, and although magnetic resonance imaging documented persisting disease activity, a direct connection between the clinical course and the TCL response pattern remains yet to be shown.
A recent report (7) has described sequence motifs shared between TCR Vfl5.2-Df3-Jfl gene rearrangements in brain lesions of MS patients and MBP-specific TCL obtained from blood. We did not observe any of these motifs in our panel of TCR sequences from MBP-specific TCL. However, this may not be surprising, as none of our sequenced TCL expressed Vf5.2 (Table VI) . The nature and implications of the persistent MBP epitope dominance that we observed in some MS patients are not at present understood. It is clear, however, that the T cell response to immunodominant epitopes is by no means monoclonal. In our study, TCL recognizing dominant peptides were heterogeneous with respect to peptide fine specificity, TCR usage, and MHC restriction. This is in line with previous reports ( 14, 15, 35) demonstrating heterogeneous TCR / gene rearrangements of T cells responding against identical MBP peptides.
Recognition of dominant epitopes is commonly observed in rodent experimental autoimmune encephalitis, where it seems to be a genetically controlled feature of immune reactivity. In H-2U mice, for example, almost all encephalitogenic T cells recognize MBP epitopes within sequence 1-1 1, whereas in H-2s mice epitopes nested in sequence 89-109 appear to dominate the MBP-specific T cell response (34) .
The epitope dominance in Lewis rats (42, 43) and PL/J mice (44) has two features, which may be relevant to understand the epitope dominance observed in our MS patients. First, we found recently that in the Lewis rat, epitope dominance is not a property of the naive T cell repertoire, but develops upon immunization in vivo. TCL isolated from MBPprimed rats show specificity to epitopes in sequence 68-88, whereas TCL from naive animals display much broader epitope patterns (J. Lannes-Vieira and H. Wekerle, manuscript in preparation). Second, in rodents with MBP-induced experimental autoimmune encephalitis, the initial monospecific MBP response seems to degenerate with time and, in addition, T cell responses to other myelin autoantigens develop (45, 46) .
It is tempting to speculate that the examples of persistent epitope dominance that we observed in the T cell repertoire of some MS patients might be involved in the pathogenesis ofthe disease. The strictly dominant epitope recognition, with no "epitope spreading" (47) over time, could reflect a sustained, active immune process. Clearly, this possibility has to be corroborated by additional evidence before immunotherapies can be targeted against the TCL recognizing clustered epitopes (48) (49) (50) (51) (52) .
